Swiss biotech firm Numab Therapeutics and Ono Pharmaceutical (TYO: 4528) have reached a research and option agreement to identify and develop an immuno-oncology candidate using the former company’s drug discovery platform.
Under the terms of the agreement, Japanese drugmaker Ono will obtain an option to acquire intellectual property rights to, and exclusive rights to develop and commercialize, the selected lead compound generated through the collaboration.
Ono will pay to Numab research funding and up to 258 million Swiss francs ($259 million) in upfront and milestone payments, as well as royalties on sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze